PDCD1 and non-small cell lung carcinoma: Similar to nivolumab, promising results have been obtained in trials testing another PD-1 inhibitor, pembrolizumab [13], and a PD-L1 inhibitor, atezolizumab (ClinicalTrials.gov number, NCT01903993), in patients with advanced NSCLC.